Literature DB >> 22393992

HLA class II variants in Chinese breast cancer patients.

Xue-Xi Yang1, Hua-Zheng Pan, Pei-Yi Li, Fen-Xia Li, Wei-Wen Xu, Ying-Shong Wu, Guang-Yu Yao, Ming Li.   

Abstract

Alterations of human leukocyte antigen (HLA) class II molecules are relevant to the development of breast cancer and metastatic progression. However, the role of HLA class II polymorphisms in the pathogenesis and progression of breast cancer is unclear. This study aimed to investigate the association between HLA class II variants and breast cancer susceptibility and prognosis in a Chinese population. Sixteen variants in HLA class II were detected with the Sequenom MassArray® iPLEX System in 216 breast cancer patients and 216 healthy controls. An association analysis based on unconditional logistic regression was carried out to determine the odds ratio (OR) and 95% confidence interval (95% CI) for each SNP. Stratified analysis by oestrogen receptor (ER) and progesterone receptor (PR) status was also performed. Among 16 variants, only seven conformed to Hardy-Weinberg proportions in the controls. None of these seven variants showed statistically significant differences between the case and control groups in this Han Chinese population. However, chr6_32737733, a variant in HLA-DQB1, showed significant associations with both ER-negative and PR-negative breast cancer in the best fit to the dominant model. Furthermore, another significant correlation was seen between chr6_32606112, a variant in HLA-DRB5, and PR positivity. These results indicate that although no breast cancer risk variants in HLA class II were found in this Chinese population, HLA-DQB1 chr6_32737733 may be involved in determining a poor prognosis, whereas HLA-DRB5 chr6_32606112 may relate to a good prognosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22393992

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

1.  Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing.

Authors:  Yogender Shokeen; Neeta Raj Sharma; Abhishek Vats; Vibha Taneja; Sachin Minhas; Mayank Jauhri; Satish Sankaran; Shyam Aggarwal
Journal:  Ethiop J Health Sci       Date:  2018-03

2.  HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation.

Authors:  Josefa A Rodríguez
Journal:  Oncol Lett       Date:  2017-08-21       Impact factor: 2.967

3.  Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer.

Authors:  Xiao-Ran Liu; Ru-Yan Zhang; Hao Gong; Hope S Rugo; Ling-Bo Chen; Yuan Fu; Jian-Wei Che; Jian Tie; Bin Shao; Feng-Ling Wan; Wei-Yao Kong; Guo-Hong Song; Han-Fang Jiang; Guo-Bing Xu; Hui-Ping Li
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

4.  Association between DLA-DRB1.2 allelic diversity and development of mammary gland tumors in dogs.

Authors:  Seyed Milad Vahedi; Gholamreza Nikbakht; Shahram Jamshidi; Leila Lankarani; Nika Alimi; Atefeh Esmailnejad
Journal:  Acta Vet Scand       Date:  2019-11-14       Impact factor: 1.695

5.  The Weight of HLA-DPA1 rs3077 Single Nucleotide Polymorphism in Prostate Cancer, a Multicenter Study.

Authors:  Mohammed Jayed Alenzi; Amany A Ghazy; Diaa-Eldin Taha
Journal:  Prostate Cancer       Date:  2021-04-21

6.  Relevance of the MHC region for breast cancer susceptibility in Asians.

Authors:  Mikael Hartman; Jingmei Li; Peh Joo Ho; Alexis Jiaying Khng; Benita Kiat-Tee Tan; Ern Yu Tan; Su-Ming Tan; Veronique Kiak Mien Tan; Geok Hoon Lim; Kristan J Aronson; Tsun L Chan; Ji-Yeob Choi; Joe Dennis; Weang-Kee Ho; Ming-Feng Hou; Hidemi Ito; Motoki Iwasaki; Esther M John; Daehee Kang; Sung-Won Kim; Allison W Kurian; Ava Kwong; Artitaya Lophatananon; Keitaro Matsuo; Nur Aishah Mohd-Taib; Kenneth Muir; Rachel A Murphy; Sue K Park; Chen-Yang Shen; Xiao-Ou Shu; Soo Hwang Teo; Qin Wang; Taiki Yamaji; Wei Zheng; Manjeet K Bolla; Alison M Dunning; Douglas F Easton; Paul D P Pharoah
Journal:  Breast Cancer       Date:  2022-05-11       Impact factor: 3.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.